Datasets:
Upload domains/glp1-obesity/learning-graph.csv with huggingface_hub
Browse files
domains/glp1-obesity/learning-graph.csv
CHANGED
|
@@ -129,3 +129,19 @@ ConceptID,ConceptLabel,Dependencies,TaxonomyID
|
|
| 129 |
128,Compounded semaglutide controversy,99|89,ACCESS
|
| 130 |
129,Prior authorization burden GLP-1,89|21,ACCESS
|
| 131 |
130,Employer coverage expansion GLP-1,89|88,ACCESS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 129 |
128,Compounded semaglutide controversy,99|89,ACCESS
|
| 130 |
129,Prior authorization burden GLP-1,89|21,ACCESS
|
| 131 |
130,Employer coverage expansion GLP-1,89|88,ACCESS
|
| 132 |
+
131,Orforglipron (Foundayo),39,DRUG
|
| 133 |
+
132,Foundayo FDA approval first oral small-molecule GLP-1 Q1 2026,131,APPROVAL
|
| 134 |
+
133,Small molecule GLP-1 hepatic first-pass metabolism,131,DRUG
|
| 135 |
+
134,CYP3A4 metabolic pathway oral GLP-1 small molecule,133,DRUG
|
| 136 |
+
135,Oral GLP-1 injection barrier elimination,131|34,ACCESS
|
| 137 |
+
136,Oral GLP-1 patient adherence advantage,135|131,ACCESS
|
| 138 |
+
137,Oral GLP-1 prior authorization redesign cascade,131|129,ACCESS
|
| 139 |
+
138,Oral GLP-1 formulary step therapy revision,137|131,ACCESS
|
| 140 |
+
139,Injectable GLP-1 premium compression risk,131|88,ACCESS
|
| 141 |
+
140,Retatrutide competitive benchmark raised by oral GLP-1,91|131,PIPELINE
|
| 142 |
+
141,TRIUMPH trial efficacy bar post-Foundayo,140|92|131,PIPELINE
|
| 143 |
+
142,Mounjaro tirzepatide Q1 2026 revenue 8.7B USD,31,MARKET
|
| 144 |
+
143,Zepbound tirzepatide obesity Q1 2026 revenue 4.2B USD,31|110,MARKET
|
| 145 |
+
144,Eli Lilly 2026 annual guidance raised 82-85B,142|143,MARKET
|
| 146 |
+
145,GLP-1 market revenue inflection point 2026,144|26,MARKET
|
| 147 |
+
146,Oral GLP-1 total addressable market expansion,131|145|135,MARKET
|